Can the Reduction of Iron Availability Caused by Tea Consumption Change the Gut Microbiota Composition and Disrupt Host Body-iron Status

A Double-blind Placebo Controlled Study to Determine the Effect of Tea Consumption on Gut Microbiota Composition and Body-Iron Status

Iron is an essential micronutrient for nearly all living organisms, including microbes. The adult human body contains approximately 3-5 g of iron (45-55 mg/kg of body weight in adult women and men, respectively). Iron-deficiency related anaemia (IDA) is a major public health problem that affects more than 2 billion people globally and this represents 24.8% of the world's population. According to World Health Organisation (WHO), iron deficiency is the most common cause of anaemia worldwide, with infants, children and women at higher risk, making it a global public health problem. Much iron deficiency is a result of poor iron dietary absorption since iron is poorly absorbed (~15%). Absorption inhibition factors (iron chelators) like phytate and tannins, found in tea and vegetables have been reported to act as potent iron uptake inhibitors. Despite its health benefits, tea-containing polyphenols (tannins) have been associated with reduction and disruption of iron absorption, acting as inhibitors of non-haem iron uptake, potentially resulting in poor iron status. However, most studies on the effect of tea on iron absorption are largely based on isotope-labelled single meal studies and animal studies. Iron is a requirement of many microorganisms, as such changes in iron availability can also have an impact on the gut microbiota. Long-term controlled human intervention studies to investigate the effect of tea on iron absorption and the effect on gut microbiota composition are scarce. In addition, the impact of dietary tannins on the gut microbiota is not understood. Thus, this proposed human intervention trial will investigate the combined effect of tea-tannins on iron status, inflammation and gut microbiota composition. This will be the first study to consider this combination of factors.

Study Overview

• Status: Not yet recruiting
• Conditions: Focus of Study: 1- Effect of Tea Consumption on Gut Microbiota; Focus of Study: 2- Effect of Tea Consumption on Body-iron Status
• Intervention / Treatment: Dietary supplement: Black tea; Dietary supplement: Placebo

• Study Type: Interventional
• Enrollment (Anticipated): 40
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United Kingdom
  • Reading, United Kingdom
    • University of Reading
    • Contact: Amro Duhduh; Phone Number: 07950285776; Email: a.duhduh@pgr.reading.ac.uk
    • Contact: Andrea Monteagudo; Email: a.monteagudo@reading.ac.uk
    • Principal Investigator: Simon Andrews
    • Sub-Investigator: Gemma Walton

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age: 18-60 years
• Gender: Male or Female
• Volunteers agree to sign an informal written consent form
• General good health
• Normal haemoglobin and serum ferritin levels

Exclusion Criteria:

• Regular tea drinkers
• Use of antibiotics, prebiotics or probiotics (in food products or as supplements), laxatives, anti-spasmodic, anti-diarrhoea drugs, (e.g. Orlistat, Lactulose) in the last 4 weeks prior to, or during the study period.
• Use of any iron supplement in the last 6 months prior to the study period.
• If participants have received bowel preparation for investigative procedures in the 4 weeks prior to the study.
• Surgical resection of any part of the bowel.
• If you have any chronic gut disorder/disease, such as IBS, IBD, etc. or other conditions that might affect the gut environment, e.g. coeliac disease. If participants are taking any medication that could affect the iron absorption (e.g. lansoprazole, omeprazole). Those with gluten allergies (e.g. Celiac disease) must be excluded as the placebo may contain gluten
• If participants are pregnant or are lactating.
• If participants have a BMI > 30 kg/m2.
• Severe allergy or any history of severe abnormal drug reaction, drug or alcohol abuse

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Black tea group; Volunteers meeting inclusion/exclusion criteria will be given an appropriate number of black tea samples twice a day with main meals for the 4 weeks of the treatment.	Dietary supplement: Black tea; Black tea twice a day for 4 weeks
Placebo Comparator: Placebo group; Volunteers meeting inclusion/exclusion criteria will be given an appropriate number of placebo tea samples twice a day with main meals for the 4 weeks of the treatment.	Dietary supplement: Placebo; Placebo tea twice a day for 4 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Composition and diversity of the faecal microbiota of the individuals consuming tea/placebo during the 4 weeks intervention	Changes in composition and diversity of faecal microbiota in response to black tea intervention assessed by next generation sequences NGS	4 weeks intervention
Levels of faecal and urine metabolites of the individuals consuming tea/placebo during the 4 weeks intervention	Changes of metabolic profile during the intervention will be estimated in faecal and urine samples using Nuclear Magnetic Resonance (NMR)	4 weeks intervention
Levels of ferritin (ng/mL) as body-iron status indicators of the individuals consuming tea/placebo during the 4 weeks intervention	Ferritin will be monitored through blood samples collected during study visits.	4 weeks intervention
Changes in the concentration (pg/mL) of inflammation markers in plasma of the individuals consuming tea/placebo using enzyme-linked immunosorbent assays (ELISAs)	gut inflammation will be assessed by measuring concentration (pg/mL) of gut inflammatory markers as plasma intestinal fatty acid-binding protein and cytokines from plasma (e.g. IL-10, IL-6, TNFα). Samples will be analysed using enzyme-linked immunosorbent assays (ELISAs)	4 weeks intervention
Changes in the concentration (mcg/g) of faecal calprotectin (gut inflammatory marker) during tea intervention using enzyme-linked immunosorbent assays (ELISAs)	Gut inflammation will be assessed measuring concentration (mcg/g) of calprotectin. Increase in the levels of Calprotectin indicates the migration of neutrophils to the intestinal mucosa, which occurs during intestinal inflammation.	4 weeks intervention

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of stool consistency	The Bristol stool chart will be provided to volunteer to measure stool consistency, the chart rate the stool consistency from 1-7 (solid - liquid) based on the shape of stool.	4 weeks intervention
Assessment of gastrointestinal symptoms	Daily assessment of gastrointestinal symptoms (abdominal pain, bloating or flatulence) will be recorded daily using daily diary.	4 weeks intervention

Collaborators and Investigators

• Sponsor: University of Reading
• Collaborators: Unilever R&D

Study record dates

Study Major Dates

• Study Start (Anticipated): September 20, 2021
• Primary Completion (Anticipated): December 10, 2021
• Study Completion (Anticipated): January 10, 2022

Study Registration Dates

• First Submitted: June 15, 2021
• First Submitted That Met QC Criteria: August 17, 2021
• First Posted (Actual): August 25, 2021

Study Record Updates

• Last Update Posted (Actual): August 25, 2021
• Last Update Submitted That Met QC Criteria: August 17, 2021
• Last Verified: August 1, 2021

More Information

Terms related to this study

• Other Study ID Numbers: UREC 20/04

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes
• IPD Sharing Supporting Information Type: Study Protocol; Statistical Analysis Plan (SAP); Informed Consent Form (ICF)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No